Loading…
Non-binding term sheet signed for oral cancer immunotherapy platform.
OSR Holdings, Inc.'s subsidiary Vaximm has entered into a non-binding term sheet with BCM Europe to explore a potential exclusive global licensing agreement for VXM01, an oral cancer immunotherapy platform. The agreement, if finalized, would grant BCM Europe exclusive rights to develop and commercialize VXM01 globally.
The non-binding term sheet outlines the initial terms and conditions for the potential licensing agreement, though no financial details have been disclosed. The collaboration aims to leverage BCM Europe's expertise in oncology to advance VXM01 through clinical development and into the market.
OSR Holdings, Inc. has a free float of 7,850,500 shares and 25,672,800 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.